Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2017-05-16 Board/Management Inform…
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The key content is the election of a new independent director to the Board of Directors, Dr. Hari Kumar. This is an announcement of a change in the company's board composition. The document does not contain financial statements or detailed management discussion, nor is it an earnings release or annual report. The primary focus is on the board/management change. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2754 characters, which is consistent with a brief announcement rather than a full report.
2017-05-16 English
Regulatory Filings 2017
Regulatory Filings
2017-05-09 English
FORM 10-Q FOR PERIOD ENDED MARCH 31, 2017
Interim / Quarterly Report Q3 2017
2017-05-09 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 7, 2017. It reports the creation of direct financial obligations through agreements to defer payment of accrued salaries with promissory notes. The content focuses on financing arrangements and obligations rather than financial results, management changes, or other categories. The document length is 3216 characters, which is relatively short but contains substantive information about financing agreements. Therefore, it fits best under Capital/Financing Update (CAP) as it details new financial obligations and promissory notes entered by the company.
2017-04-10 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed by BioVie Inc. dated April 3, 2017. It includes a prospectus supplement and references a press release about FDA and USPTO notifications related to the company's drug candidate. The content is an update on corporate events and regulatory notices rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis. The document is primarily a regulatory announcement of other events and includes a press release as an exhibit. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-04-03 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes announcements about FDA approval to initiate a clinical trial and a patent allowance notice from the USPTO. There are no financial statements or detailed financial data presented. The document is relatively short (2963 characters) and includes a press release as an exhibit. This type of filing is typically categorized as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2017-04-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.